Peijia Medical

Peijia Medical is a global provider of medical innovation solutions. Adhering to the philosophy of "Striving for perfection, respecting life," it is committed to continuous innovation to deliver safe, effective, and accessible products and solutions for patients, alleviating their suffering and improving their quality of life. The company aims to become a patient-centered, originality-driven, and respected global high-tech medical enterprise. Established in 2012, its headquarters is located in Suzhou, China. In May 2020, Peijia Medical was listed on the Main Board of the Hong Kong Stock Exchange, with the stock code 9996.HK. Peijia Medical strategically positions itself with an "innovation-driven, heart-brain co-treatment" approach, focusing on the innovation, research, development, and production of advanced medical devices in the fields of structural heart disease and cerebrovascular intervention. Its product portfolio includes aortic valves, mitral valves, tricuspid valves, surgical accessories, as well as cerebrovascular intervention products for hemorrhagic, ischemic, and access-related conditions. All three generations of its aortic valve systems have been approved by the National Medical Products Administration (NMPA) as innovative medical devices. With a global perspective, Peijia Medical leads innovation by establishing global innovation centers and R&D facilities in countries such as the United States, Canada, and France, where cutting-edge technology research and product development are conducted. The company possesses unique comparative advantages in areas such as biomaterial processing technology, precision manufacturing capabilities, quality management systems, and patent portfolios. It operates GMP-standard advanced medical device production (R&D) bases in Shanghai and Suzhou, China, and its products have been distributed to thousands of hospitals across the country.